Newsfile Corp
23 Aug 2026, 11:06 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CVS Caremark has delayed its decision on expanded insurance coverage for ARS Pharmaceuticals' product, neffy, until January 2027. — Delayed insurance coverage directly impairs revenue projections and market penetration for a key product.
-0.80ARS Pharmaceuticals is facing a federal securities class action lawsuit alleging that executives concealed material adverse facts regarding the neffy coverage timeline. — Securities litigation creates significant legal liability and undermines investor confidence in corporate governance.
-0.60The disclosure of the lack of commercial formulary additions for neffy in the July 1, 2026 cycle resulted in a 23.9% drop in stock price. — The immediate market reaction confirms the material importance of the coverage timeline to the company's valuation.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities class action lawsuit alleging fraud and misleading statements, coinciding with a significant stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
